Please login to the form below

Not currently logged in
Email:
Password:

Kite bags $90m upfront in two Asian deals for lead CAR-T drug

Partners with Daiichi Sankyo and Fosun Pharma to focus in on non-Hodgkin lymphoma

Kite PharmaKite Pharma has forged cancer immunotherapy alliances in Japan and China as it expands its business into Asian markets.

In China, Kite has formed a joint venture with Chinese drugmaker Fosun Pharma to develop lead chimeric antigen receptor T cell (CAR-T) therapy axicabtagene ciloleucel (also known as KTE-C19), which has been submitted for approval in the US via a rolling marketing application.

That deal nets the US biotech $40m in upfront payments, plus $20m of funding to support clinical development and manufacturing and $35m in regulatory and commercial milestones, and Kite will own 50% of the new company.

The Shanghai-based JV has also taken an option to develop two other candidates - KITE-718, a MAGE A3/A6-directed therapy for solid tumours, and KITE-439, which targets human papillomavirus type 16 E7 oncoprotein. Opt-in and milestone payments for these two candidates could reach $140m.

Kite's Japanese partnership is with Daiichi Sankyo and will see Kite receive $50m upfront and $200m in development and commercial milestone payments in return for rights to axicabtagene ciloleucel. Daiichi Sankyo is also taking an option to license KITE-718 plus "certain other product candidates that proceed to a US investigational new drug application filing over the next three years".

Kite has submitted axicabtagene ciloleucel as a treatment for patients with refractory aggressive non-Hodgkin lymphoma (NHL) in the US, and is vying with Novartis to be the first company to win marketing approval anywhere in the world for a CAR-T therapy.

The therapy involves harvesting patient's T cells and engineering them to express a chimeric antigen receptor (CAR) that targets CD19, an antigen expressed on the cell surface of B-cell lymphomas and leukaemias, which redirects the T cells to kill cancer cells.

The two new deals could unlock a sizeable new patient population for axicabtagene ciloleucel - there are approximately 73,000 newly-diagnosed cases of NHL in China each year, while Japan has around 9,300 new cases.

Article by
Phil Taylor

11th January 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

Personalised medicine: driving a need for greater diversity in clinical trials
Kate Shaw, Innovative Trials' Founder & CEO, investigates one of the biggest challenges facing clinical research today....
Congresses and conferences
Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...